Recent events
Recent events tied to this brand in public sources.
Back to profile21 entries · Page 1 of 2
2021
Catalent launches OptiDose Design Solution
Catalent announced the launch of its OptiDose Design Solution, a dose-form design solution intended to combine data-driven scientific tools with Catalent's development expertise. It is available throughout Catalent's global oral dose network.
2021
Catalent launches GPEx Lightning cell line development technology
Catalent announced the launch of GPEx Lightning, a next-generation cell line development technology that it says can shorten drug-substance development by up to three months compared with previous timelines.
2021
Catalent receives RoSPA Gold Health and Safety Award
Catalent announced that it had received the RoSPA Gold Health and Safety Award for its work to provide a safe, healthy and inclusive working environment. The award presentation was scheduled for September 9, 2021.
2021
Catalent acquires HCTS and its Gosselies facility
Catalent acquired Promethera's cell therapy manufacturing subsidiary, Hepatic Cell Therapy Support SA (HCTS), including its facility in Gosselies, Belgium.
2021
Catalent and Janssen expand vaccine manufacturing partnership
Catalent announced an expanded partnership with Janssen to increase manufacturing capacity for Janssen's COVID-19 vaccine at Catalent's Anagni, Italy facility, including vial-filling, inspection, labeling, and packaging services. An additional high-speed vial-filling line was expected to be operational in the fourth quarter of 2021.
2021
Acorda and Catalent enter global supply agreement for INBRIJA
In connection with the sale of Acorda's manufacturing operations, Acorda and Catalent entered a long-term global supply agreement under which Catalent will manufacture and package INBRIJA for Acorda.
2021
Acorda completes sale of manufacturing operations to Catalent
Acorda Therapeutics announced that it had completed the sale of its manufacturing operations in Chelsea, Massachusetts, to Catalent for $80 million in cash.
2021
Acorda announces agreement to sell Chelsea manufacturing operations
Acorda announced a definitive agreement to sell its INBRIJA manufacturing operations in Chelsea, Massachusetts, to Catalent for $80 million in cash. Completion remained subject to customary closing conditions and was expected in the first quarter of 2021.
2021
Acorda and Catalent enter long-term INBRIJA supply agreement
Acorda and Catalent entered into a long-term global supply agreement under which Catalent will manufacture and package INBRIJA for Acorda.
2020
Catalent announces OptiGel DR technology launch
Catalent announced the launch of OptiGel DR technology for formulating and manufacturing delayed- or enteric-release softgels. The technology combines pectin with gelatin in the softgel capsule, eliminating the need for a separate capsule-coating step.
2020
Catalent launches OneXpress service
Catalent announced the launch of OneXpress, a service for integrated development, scale-up and manufacturing of new oral solid dosage forms.
2020
Catalent acquires Bloomington manufacturing facility
Catalent announced that it had acquired a manufacturing facility in Bloomington, Indiana, from AB BioTechnologies, Inc. and its affiliate. The acquisition is part of a $14 million investment to build out and qualify the site as a North American center of excellence for early-phase clinical biologics formulation development and drug product fill/finish services.
2020
Moderna announces vaccine manufacturing collaboration with Catalent
Moderna announced a collaboration with Catalent for large-scale manufacturing of its potential COVID-19 vaccine. Catalent was to handle vial filling and packaging and provide staffing to support production of an initial 100 million doses.
2020
Catalent and ViralClear agree to develop potential COVID-19 treatment
Catalent announced an agreement with ViralClear Pharmaceuticals to work on developing two oral dosage forms of merimepodib, a potential treatment for adults with advanced COVID-19.
2020
Catalent and Spicona sign vaccine-development agreement
Catalent announced that it signed an agreement with Spicona to develop a virus-like protein-based vaccine against COVID-19.
2020
Catalent appoints Charles Lickfold as CIO
Catalent announced Charles Lickfold's appointment as Senior Vice President and Chief Information Officer. He succeeds John McGill, who plans to retire in September 2020.
2020
Catalent announces planned acquisition of a Japanese clinical packaging facility
Catalent announced a deal to acquire a clinical packaging facility in Minakuchi, Japan, from Teva-Takeda Pharmaceuticals. The planned purchase is intended to establish a clinical GMP manufacturing and distribution hub; the deal was expected to close on July 1, 2020.
2020
Catalent supports Humanigen’s Phase 3 lenzilumab study
Catalent provided clinical supply support to Humanigen and its partners for the Phase 3 study of lenzilumab.
2020
Catalent appoints Jim Walter as operations vice president
Catalent announced Jim Walter's appointment as Vice President of Operations for its Oral and Specialty Delivery business, with operational responsibility for five facilities.
2019
Catalent launches CTSuccess clinical trial planning service
Catalent announced the launch of CTSuccess, a clinical trial planning service intended to support sponsors with supply-chain planning and reduce the risk of delays and budget overspend.